Ardisia

Ardisia: A Comprehensive Reference

1. Identity and Botanical Classification

Taxonomic Position and Accepted Species

Ardisia is a large genus of Primulaceae, with 734 accepted species worldwide. Older literature placed the genus in the family Myrsinaceae, but modern molecular taxonomy has reclassified Myrsinaceae within the broader family Primulaceae; both family designations appear in the scientific literature depending on publication date. The genus Ardisia, consisting of approximately 500 species, was historically regarded as the largest genus in the Myrsinaceae family. Members of the genus are shrubs, subshrubs, or small trees, and the genus is distributed pan-tropically.

The medically most-studied species include:

• Ardisia japonica (Thunb.) Blume — Japanese ardisia; known in Chinese as zǐjīn niú (紫金牛) or Ai Di Cha (矮地茶); one of the 50 Fundamental Herbs of Traditional Chinese Medicine (TCM).
• Ardisia crenata Sims — coral bush, coralberry, spiceberry, Christmas berry; native to the Yangzi River valley in China.
• Ardisia crispa (Thunb.) A.DC. — known in Malaysia as Mata Itik or Mata Ayam ("hen's eyes").
• Ardisia gigantifolia Stapf — used in Zhuang and other Southern Chinese folk medicine.
• Ardisia hanceana Mez — known as Da-luo-san.
• Ardisia compressa Kunth — used in Latin American traditional medicine.
• Ardisia sieboldii — studied for resorcinol and alkylbenzoquinone compounds.

Common Names and Preparations

Ardisia japonica is commonly referred to as "Ai Di Cha," with various folk records and classical herbal texts documenting alternative names such as Ping Di Mu, Ye Di Hong, Ai Cha Feng, and Ai Cha He. Ardisia crenata Sims, also known as the coral bush, coralberry, hen's eyes, and spiceberry, is native to the Yangzi River valley in China.

Commercially and clinically, Ardisia species are used as dried whole herbs, dried roots, decoctions (water-based preparations), ethanol or methanol extracts, and formulated proprietary medicines. The official drug material of A. japonica is the dried whole plant; it is harvested during the summer and autumn when the stems and leaves are lush, then the dirt is removed and it is dried. Myriad cultivars of three species (Ardisia japonica Blume, Ardisia crispa A.DC., and Ardisia crenata Sims) have been developed through breeding and subsequent selection in Japan, where these plants have been appreciated for their long-persisting fruits and foliage since the 18th century.

2. Traditional and Historical Use

East Asian (Chinese) Medicine

Ardisia has a medicinal history of nearly a thousand years, mainly for treating diseases of injuries, the musculoskeletal system, and the symptomatic system in Zhuang medicine. A. japonica has a long-standing history of medicinal use, with its earliest recorded mention appearing in the renowned Song Dynasty pharmacopoeia Ben Cao Tu Jing (1061 AD). This classic medical book described its efficacy in alleviating coughs, promoting expectoration, and relieving asthma.

The Chinese ancient medicine book Compendium of Materia Medica records that A. japonica has the effect of "detoxification and promoting blood circulation." The whole plants of A. japonica are listed in the Chinese Pharmacopoeia (2020 version) as a traditional Chinese medicine to cure phlegm, cough, jaundice, edema, and bruise.

Ardisia japonica is a well-known traditional Chinese medicinal herb used as a diuretic, for treating cough, and for stopping uterine bleeding. The whole plant is used as a bacteriostatic, tuberculostatic, hemostatic, and antiasthmatic drug in the treatment of tuberculosis, chronic asthma, and other diseases of the respiratory tract.

Plants such as A. crenata, A. gigantifolia, and A. japonica are also commonly used in folk Zhuang medicine formulas to treat musculoskeletal, injury, respiratory, and urinary system diseases. In contemporary Chinese clinical practice, A. japonica is widely applied in the treatment of respiratory diseases and liver disorders. Currently, 23 proprietary Chinese medicines containing A. japonica have been developed and marketed in China for respiratory disease treatment.

Ardisia gigantifolia Stapf, Ardisia hanceana Mez (Da-luo-san), and Ardisia crenata Sims (Xiao-luo-san) are commonly used in folk medicine for the treatment of rheumatism. In folklore, A. hanceana and A. crenata are used together with the saying "Use Da-luo-san and Xiao-luo-san together for better rheumatism treatment."

Southeast Asian and Indo-Chinese Traditional Use

Ardisia crispa (Thunb.) A.DC. (Primulaceae) is a medicinal herb traditionally used by Asian people as a remedy to cure inflammatory-related diseases, including rheumatism. In the Indo-China region, locals treat chest illnesses with the plant root extract, while Taiwanese use it as a diuretic and antidote for poison. Ardisia crispa is used mostly in some parts of the Asian region by traditional practitioners to treat certain diseases associated with oxidative stress and inflammation, including cancer and rheumatism. In Malaysia, it is popularly known as "Mata Ayam," and local traditional practitioners believe that the root of the plant is therapeutically beneficial.

A. crispa is believed to be useful in the treatment of several human ailments such as liver cancer, swelling, rheumatism, cough, fever, diarrhea, broken bones, women's dysmenorrhea, respiratory tract infections, and traumatic injuries.

Wider Ethnomedicinal Context

Ardisia species are widely distributed throughout tropical and subtropical regions of the world and have been used for the treatment of cancer, hypertension, irregular menstruation, gonorrhea, diarrhea, and postnatal syndromes, among others. Traditional medicinal uses attributed to Ardisia also include alleviation of liver cancer, swelling, rheumatism, earache, fever, broken bones, dysmenorrhea, inflammation, pain, snake and insect bites, birth complications, and improving general blood circulation.

3. Key Constituents and Active Compounds

Overview of Phytochemical Diversity

Ardisia species produce several groups of biologically active phytochemicals including saponins, coumarins, and quinones. Phytochemical studies of Ardisia species have resulted in the isolation and identification of 111 compounds, including triterpenoid saponins, quinones, phenols, coumarins, cyclic depsipeptides, and flavonoids. More recently, a comprehensive review documented that a total of 296 compounds have been isolated from A. japonica, including triterpenes and glycosides, flavonoids, phenols and phenolic acids, coumarins, quinones, and volatile oils.

From Zhuang medicinal herbs of Ardisia alone, approximately 938 compounds from different plant parts have been catalogued, including triterpenoids, phenolics, and volatile oils.

Principal Bioactive Compounds

Triterpenoid Saponins

Triterpenoid saponins are considered among the most pharmacologically significant constituents of the genus. Key saponins identified include ardisiacrispin A and ardisiacrispin B, found predominantly in the roots of A. crispa and A. crenata. Phytochemical studies of Ardisia crispa have characterized two utero-contracting triterpenoid saponins (ardisiacrispin A and ardisiacrispin B) from the plant's root. Ardisiacrispin A exhibits cytotoxic and uterotonic activities, whereas ardisiacrispin B demonstrates cytotoxic and anti-inflammatory effects. The content of ardisiacrispin B in Ardisia crenata Sims is as high as 16.27%, making it one of the main components of this herbal medicine.

Other triterpenoid saponins isolated from the genus include ardisicrenosides and ardipusillosides. Ardisiacrispin B is found in several species of the Ardisia genus, including Ardisia crenata Sims, Ardisia crispa (Thunb.) A.DC., and Ardisia mamillata Hance. The roots of both red-berried and white-berried varieties of A. crenata are rich sources of these compounds. Ardisiacrispin A content amounted to 22.17±4.75 and 25.72±1.46 mg/g dry weight in roots of red-berried and white-berried ardisia varieties, respectively.

Bergenin

Bergenin (also written norbergenin in some contexts) is a C-glycoside of 4-O-methyl gallic acid and a prominent marker compound across multiple Ardisia species. Compounds isolated from Ardisia japonica include bergenin, embelin, ardisin, ardisinol I and II, myricitrin, quercetin, quercetrin, and rapanone. Bergenin exhibits antiviral, antifungal, antitussive, antiplasmodial, anti-inflammatory, antihepatotoxic, antiarrhythmic, antitumor, antiulcerogenic, antidiabetic, and wound-healing properties. In addition, bergenin has shown potential antimalarial, antileishmanial, trypanocidal, antiviral, antibacterial, antifungal, antinociceptive, antiarthritic, antiulcerogenic, antidiabetic/antiobesity, antiarrhythmic, anticancer, hepatoprotective, neuroprotective, and cardioprotective activities. Bergenin is used as a marker compound in quality-control analyses of A. japonica preparations.

Embelin (Benzoquinones and Alkylphenols)

Embelin is an alkyl benzoquinone found in the fruits of several Ardisia species. Embelin was found only in the fruits of studied Ardisia species. Embelin, a benzoquinone and a phytochemical constituent of Ardisia japonica, was found to have antibacterial activity. Research has further identified embelin as an inhibitor of the X-linked inhibitor of apoptosis protein (XIAP), giving it potential relevance in cancer biology.

Long-chain alkyl-1,4-benzoquinones, including 2-methoxy-6-undecyl-1,4-benzoquinone (AC2) and 2-methoxy-6-tridecyl-1,4-benzoquinone, are major constituents of A. crispa roots. The root part of A. crispa has been reported to contain 2-methoxy-6-tridecyl-1,4-benzoquinone, with documented antimetastatic and antitumor effects.

FR900359 (Cyclic Depsipeptide)

FR900359 is a structurally unique cyclic depsipeptide first isolated from A. crenata. The molecular structure and absolute configuration of FR900359, a novel cyclic depsipeptide from Ardisia crenata sims, has been determined by a combination of X-ray crystallographic analysis and GC/MS study of the diastereomeric derivatives of its constituents. FR900359 has attracted substantial research interest as a potent and selective inhibitor of the Gq family of heterotrimeric G proteins. A cyclic depsipeptide, FR900359, isolated from Ardisia crenata was evaluated for vasorelaxant effects on rat aortic arteries and caused concentration-dependent relaxation (1 nM–10 μM) in phenylephrine-precontracted endothelium-intact aortic rings. This biological peptide may block platelet aggregation. It has structural similarities with ardisicrenosides C and D, which have an inhibitory effect on cAMP phosphodiesterase.

Ardisin and Rapanone

Ardisin, a compound originally isolated from Ardisia japonica, may contribute to cancer prevention and treatment, and is also found in Ardisia compressa. Rapanone is a further benzoquinone found in A. japonica with reported pharmacological activity.

Flavonoids, Phenolic Acids, and Other Compounds

Additional compounds elucidated from Ardisia crispa roots include wogonin, oroxylin A, wogonoside, baicalin, (+) anwulignan, meso-dihydroguaiaretic acid, 4-hydroxyvaleric acid, bergenin, β-sitosterol, and ardisiacrispin C. From an aqueous extract of A. japonica, 94 compounds were identified, including terpenoids, phenylpropanoids, alkaloids, and fatty acyl compounds. Flavonoids such as quercetin, myricitrin (myricetin-3-rhamnoside), and isoquercitrin are also constituents of A. japonica and contribute to its antioxidant activity.

4. Mechanisms of Action

Anti-inflammatory Mechanisms

Resorcinol and alkylbenzoquinone derivatives from Ardisia species exhibit anti-inflammatory effects through inhibiting protein denaturation (IC50 values of 5.8–9.6 μM), cyclooxygenase-2 (COX-2) activity (IC50 values of 34.5–60.1 μM), and nitrite formation in RAW 264.7 cells. The anti-angiogenic properties of Ardisia crispa roots have been linked to cyclooxygenase (COX) and/or lipoxygenase (LOX) activity inhibition.

Extracts of Ardisia significantly suppressed the mRNA expression of inducible nitric oxide synthase, leading to inhibition of nitric oxide production in lipopolysaccharide-stimulated RAW 264.7 macrophages. Network pharmacology analyses have further proposed that the main active ingredients of A. japonica include sinensetin, galanin, isorhamnetin, kaempferol, wogonin, quercetin, and bergenin, targeting TP53, HSP90AA1, VEGFA, AKT1, EGFR, and PIK3CA, which are mainly enriched in the PI3K/AKT and MAPK signaling pathways that modulate the inflammatory response.

Vasorelaxation via Gq Protein Inhibition

FR900359 is recognized as an exceptionally selective inhibitor of Gq-class G proteins. The vasorelaxant effect of FR900359 is mediated through the increased release of NO from endothelial cells at low concentrations, and can be attributed to inhibitory effects on voltage-dependent Ca²⁺ channel- and receptor-operated Ca²⁺ channel-dependent Ca²⁺ influx at high concentrations.

Anti-angiogenic Mechanisms

The benzoquinone derivative AC2 isolated from A. crispa roots significantly suppressed human umbilical vein endothelial cell (HUVEC) proliferation in a time-independent manner, with an IC50 value of 1.00–1.35 μg/mL; it also induced apoptosis in HUVECs and significantly suppressed their migration, invasion, and tube formation in a concentration-dependent manner.

Lipoxygenase Inhibition

Phytochemical investigation of Ardisia japonica has resulted in the discovery of compounds that are 5-lipoxygenase inhibitors, anti-HIV agents, anti-tubercular agents, and PTP1B inhibitors.

5. Scientific Evidence by Area of Use

5.1 Respiratory Diseases (Cough, Bronchitis, Tuberculosis, Asthma)

A. japonica has demonstrated significant efficacy in treating respiratory diseases and liver disorders. Pharmacological studies have revealed that A. japonica exhibits various bioactivities including anti-inflammatory, antitussive, intervention in airway remodeling, protection against liver injury and anti-hepatic fibrosis, antibacterial, antiviral, anti-tumor, PTP1B inhibition, and antioxidant effects. It is very famous for its use in treating various respiratory tract infections such as pneumonia, bronchitis, and tuberculosis.

In the domain of respiratory disease, the most clinically relevant data concern Chinese proprietary medicines containing A. japonica. In clinical practice, A. japonica is commonly used to treat chronic bronchitis, pulmonary tuberculosis, tuberculous pleurisy, and acute icteric hepatitis. Preclinical mechanistic evidence supporting the antitussive and expectorant effects is more established than clinical trial data. Seventeen components such as caryophyllene oxide, bergenin, and gallic acid were identified as potential pharmacodynamic components with anti-inflammatory activity, and the intermediate and high doses of the ethyl acetate extract from A. japonica exhibited more pronounced effects in enhancing lung function, blood counts, and lung histology in a dose-dependent manner in an acute lung injury animal model. Evidence grade: Preclinical (animal/cell studies and observational clinical data); no large-scale controlled human trials identified.

5.2 Liver Disease (Hepatitis, Hepatocellular Carcinoma, Liver Fibrosis)

In clinical practice, A. japonica is commonly used to treat acute icteric hepatitis, and has shown remarkable curative effects in the treatment of chronic hepatitis. Network pharmacology of A. japonica in the context of autoimmune hepatitis has identified bergenin, quercetin, and kaempferol as key active components targeting hepatitis-related pathways.

In an investigation comparing the bioactivities of six species of Ardisia on human hepatoma (HepG2) cells in vitro, it was observed that the chemical constituents in A. japonica and two other species elicited the greatest inhibitory potential against liver cancer cells. Clinical studies have demonstrated that a Chinese herbal formula containing A. japonica (Ardisiae Japonicae Herba), Scutellaria barbata, Hedyotis diffusa, and 23 other herbs could improve the clinical outcome and quality of life in hepatocellular carcinoma (HCC) patients. However, this formula-based evidence does not permit attribution of observed effects to A. japonica in isolation. Evidence grade: Animal/in-vitro studies and uncontrolled clinical observations using multi-herb formulas. No rigorous clinical trials for A. japonica monotherapy are available.

5.3 Rheumatism, Arthritis, and Musculoskeletal Disorders

Ardisia crispa is a medicinal herb traditionally used by Asian people as a remedy to cure inflammatory-related diseases, including rheumatism. The plant roots possess various pharmacological activities including antipyretic, anti-inflammation, and antitumor properties.

Ardisia crispa possesses various pharmacological activities including antipyretic, antihyperalgesic, anti-inflammatory, and antitumor properties. The hexane fraction of the plant roots (ACRH) has been evidenced with potent anti-angiogenic effect in both in vitro and in vivo models of angiogenesis. Since pathological angiogenesis is a feature of rheumatoid arthritis, anti-angiogenic activity is mechanistically relevant. A. crispa roots have been identified with an isomeric mixture of viminalol (α- and β-amyrin) and a 2-methoxy-6-undecyl-1,4-benzoquinone, shown to exhibit anti-inflammatory and antihyperalgesic activities. Evidence grade: Preclinical (in vitro and in vivo animal); no human clinical trials identified.

5.4 Cancer and Cytotoxic Activity

The naturally occurring triterpene saponin ardisiacrispin B displayed cytotoxic effects in multi-factorial drug-resistant cancer cells via ferroptotic and apoptotic cell death. Assessment of cytotoxicity of ardisiacrispin A and A. crenata extracts on a panel of human cancer cell lines revealed a similar effect of root extracts from both varieties, with the highest potency against melanoma WM793 and colon cancer Caco2.

In vitro studies on A. crispa extracts against breast cancer have been conducted. Results showed that an 80% methanol extract from leaves showed the most promising anti-mammary cancer activity, with an IC50 value of 42.26 ± 1.82 μg/mL and a selective index (SI) value of 10.22. Ethyl acetate partition was cytotoxic for both cancer and normal cell lines, while the aqueous extract exhibited poor cytotoxic effect.

Resorcinol and alkylbenzoquinone compounds purified from A. sieboldii showed cytotoxicity against a panel of cancer cell lines in a dose-response manner, with compound 2 exhibiting the highest cytotoxicity on cancer cells (IC50 values of 8.8–25.7 μM).

Evidence grade: All currently available evidence for anticancer activity is limited to cell-based (in vitro) and animal studies. No clinical trials examining Ardisia as a cancer treatment in humans have been identified in the peer-reviewed literature.

5.5 Antioxidant Activity

Studies have shown the highest phenolic and flavonoid content in root extracts of Ardisia, which resulted in the most potent free radical scavenging activity as revealed by DPPH and FRAP assays. Roots and flowers showed the highest bergenin (3.36 ± 0.22 mg/g dry weight) and quercetin (2.99 ± 0.10 mg/g dry weight) content, respectively. Evidence grade: In vitro evidence; clinical relevance of antioxidant activity has not been demonstrated in human trials.

5.6 Blood Stasis and Circulatory Effects

In rats with experimentally induced blood stasis, A. japonica extract reduced the area of stasis, decreased the inflammatory reaction in the liver and lungs, lowered plasma viscosity, increased the index of erythrocyte deformability, and decreased the index of erythrocyte aggregation, suggesting an anti-blood-stasis effect. Different metabolites were identified via plasma untargeted metabolomics, and it was found that A. japonica exerts its anti-blood-stasis effect by reducing inflammatory responses through cysteine and methionine metabolism, linolenic acid metabolism, and sphingolipid metabolism. Evidence grade: Preclinical animal study with mechanistic investigation; no human clinical trial evidence identified.

5.7 Antimicrobial and Antiviral Activity

Phytochemical investigation of Ardisia japonica has resulted in the discovery of compounds that are anti-HIV and anti-tubercular agents. A dimeric lactone from A. japonica was reported to show inhibitory activity for HIV-1 and HIV-2 Ribonuclease H in vitro. Bergenin's antiviral and antibacterial properties are well documented in preclinical models. Evidence grade: In vitro; no human antimicrobial or antiviral clinical trials for Ardisia have been identified.

6. Body Systems and Health Areas Associated with Ardisia

Based on the aggregate of traditional use and preclinical evidence, Ardisia species are primarily associated with the following body systems and health domains:

• Respiratory system: Antitussive, expectorant, antiasthmatic; treatment of bronchitis, tuberculosis, and pneumonia.
• Hepatic system: Hepatoprotective, anti-fibrotic; traditional use and clinical observation in hepatitis and liver disorders.
• Musculoskeletal system: Anti-rheumatic, analgesic, anti-inflammatory; traditional use in joint pain and traumatic injury.
• Cardiovascular and circulatory system: Vasorelaxant activity (FR900359), anti-thrombotic (platelet aggregation inhibition), anti-blood-stasis.
• Immune/inflammatory system: COX-2 inhibition, 5-LOX inhibition, NF-κB pathway modulation, NOS inhibition.
• Oncology (preclinical only): Cytotoxic activity against multiple cancer cell lines via apoptosis, ferroptosis, and anti-angiogenic mechanisms.
• Urinary system: Traditional diuretic use.
• Reproductive system: Historical use for dysmenorrhea and uterine bleeding; uterotonic saponins identified.

Pharmacological activity studies have shown that this genus has anti-tumour, anti-inflammatory, anti-oxidant, anti-bacterial, and anti-microbial properties, with significant effects on respiratory, digestive, urinary, and musculoskeletal system diseases.

7. Dosage Forms and Reported Dosages

Ardisia japonica (Thunb.) Blume is a member of the Primulaceae family and a traditional Chinese herbal medicine. The entire dried plant is employed medicinally. According to Chinese traditional medicine practice references, the preparation involves collecting the whole plants, removing impurities, washing, and drying. The reported dosage in TCM is 10–15 g.

In the 2020 edition of the Chinese Pharmacopoeia, A. japonica (Ai Di Cha) is collected during summer and autumn, and the dried whole herb is the official drug material. The stem is slightly flattened and cylindrical, slightly twisted, 10–30 cm long and 0.2–0.5 cm in diameter; the surface is reddish-brown with fine longitudinal wrinkles.

For A. crispa, the root is the principal medicinal part used in Southeast Asian traditions. Hexane and ethanolic extracts of the roots have been used in preclinical studies, but no standardized human dosage has been established in the peer-reviewed literature.

In animal pharmacokinetic studies, A. japonica extract was administered orally to rats, and a validated LC-MS/MS method was applied to the pharmacokinetic study of gallic acid, bergenin, and quercetin-3-rhamnoside in rat plasma after oral administration. However, no human pharmacokinetic data with defined dose-concentration relationships were found in publicly accessible peer-reviewed sources.

Currently, 23 proprietary Chinese medicines containing A. japonica have been developed and marketed in China for respiratory disease treatment, each with its own formulation-specific dosing that would be regulated by the Chinese Pharmacopoeia standards.

8. Safety Considerations and Interactions

Uterotonic Activity

The most clearly documented safety signal for the genus relates to uterotonic effects of certain saponins. Phytochemical studies of Ardisia crispa have characterized two utero-contracting triterpenoid saponins — ardisiacrispin A and ardisiacrispin B — from the plant's root. Ardisiacrispin B has been reported in the literature to have uterotonic effects, to inhibit cancer cells, and to be cytotoxic. These uterotonic properties are relevant as a potential contraindication during pregnancy.

Renal Toxicity at High Doses

Large doses of A. japonica as medicine can be toxic to the kidneys. This caution is noted in reference sources on the plant, though dose thresholds have not been established through formal clinical toxicology studies.

Cytotoxicity Against Normal Cells

Certain extracts and isolated compounds exhibit cytotoxicity not only against cancer cells but also against normal cell lines. The ethyl acetate partition of A. crispa was cytotoxic for both cancer and normal cell lines in vitro. The selectivity indices reported in vitro do not reliably predict in vivo safety margins.

General Toxicological Research Gaps

Future research needs to include more toxicological studies, more comprehensive chemical characterization of extracts, bioavailability, extract standardization, investigation of possible herb–drug interactions, and additional human and animal studies to confirm the health-promoting properties claimed for Ardisia species. This statement from a peer-reviewed toxicology journal accurately reflects the state of the field: systematic human safety data, herb-drug interaction profiles, and standardized dosing guidance are largely absent from the published literature.

Taxonomic Confusion and Misidentification Risk

Due to taxonomic confusions, correct identification and acquisition of plant materials remain difficult for some species. Given that different species within the genus have distinct phytochemical profiles — including different concentrations of uterotonic or cytotoxic saponins — misidentification carries meaningful safety implications.

Proprietary Medicine Status in China

A. japonica is widely applied in modern clinical practice in China in the treatment of respiratory diseases and liver disorders, demonstrating significant therapeutic efficacy. Its inclusion in the Chinese Pharmacopoeia (2020 edition) means it is subject to regulatory quality standards within the Chinese TCM pharmaceutical system, but this does not constitute evaluation under the regulatory frameworks of other jurisdictions (e.g., EMA, FDA, or TGA).

References

• Tian-Liang et al. (2024). Ethnobotanical study of Zhuang medicinal herbs of Ardisia: variety systematization, traditional uses, phytochemistry, pharmacology, clinical application, and toxicity. Journal of Pharmacy and Pharmacology, 76(4), 327–353. PubMed.
• Ardisia Crispae Radix et Rhizoma: A review of botany, traditional uses, phytochemistry, pharmacology, and toxicology. Journal of Ethnopharmacology (2024). ScienceDirect.
• Kobayashi & de Mejía (2005). The genus Ardisia: a novel source of health-promoting compounds and phytopharmaceuticals. Journal of Ethnopharmacology, 96(3), 347–354. ScienceDirect.
• Liu B, Liu R, Liu Q, et al. (2022). The ethnomedicinal and functional uses, phytochemical and pharmacology of compounds from Ardisia species: An updated review. Medicinal Research Reviews, 42(5), 1888–1929. Wiley.
• Ardisia japonica (Thunb.) Blume: Traditional applications, phytochemistry, pharmacological activities, network pharmacology, and quality control. Journal of Ethnopharmacology (2025). ScienceDirect.
• Ardisia: health-promoting properties and toxicity of phytochemicals and extracts. Toxicology Mechanisms and Methods, 21(9) (2011). Taylor & Francis.
• Zaima K, et al. (2013). Vasorelaxant effect of FR900359 from Ardisia crenata on rat aortic artery. Journal of Natural Medicines, 67(1), 196–201. PubMed.
• Miyamae A, et al. (1989). Structural studies of FR900359, a novel cyclic depsipeptide from Ardisia crenata sims. Journal of the Chemical Society, Perkin Transactions 1. RSC Publishing.
• Blin JA, Hamid RA, Khaza'ai H (2021). Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro. BMC Complementary Medicine and Therapies, 21(1), 176. PMC.
• 1,4-Benzoquinone derivative isolated from Ardisia crispa root suppresses angiogenesis via angiogenic signaling cascades. Saudi Pharmaceutical Journal (2024). PMC.
• Cytotoxic and anti-inflammatory resorcinol and alkylbenzoquinone derivatives from the leaves of Ardisia sieboldii. PubMed (2019).
• Nordin ML, et al. (2018). In vitro investigation of cytotoxic and antioxidative activities of Ardisia crispa against breast cancer cell lines, MCF-7 and MDA-MB-231. BMC Complementary and Alternative Medicine, 18(1), 87. PMC.
• Cytotoxicity and Apoptosis Induction of Ardisia crispa and Its Solvent Partitions against Mus musculus Mammary Carcinoma Cell Line (4T1). PMC.
• Investigating the Underlying Mechanisms of Ardisia japonica Extract's Anti-Blood-Stasis Effect via Metabolomics and Network Pharmacology. PMC (2023).
• Discovery of the Active Compounds of the Ethyl Acetate Extract Site of Ardisia japonica for the Treatment of Acute Lung Injury. PMC (2024).
• Yu XA, et al. (2018). Simultaneous Quantification of Gallic Acid, Bergenin, Epicatechin, Epicatechin Gallate, Isoquercitrin, and Quercetin-3-Rhamnoside in Rat Plasma by LC-MS/MS Method after Oral Administration of Ardisia japonica Extract. PMC.
• Exploring the Effective Components and Mechanism of Action of Japanese Ardisia in the Treatment of Autoimmune Hepatitis Based on Network Pharmacology and Experimental Verification. Pharmaceuticals, 15(12), 1457 (2022). MDPI.
• Metabolites-Based Network Pharmacology to Preliminarily Verify In Vitro Anti-Inflammatory Effect of Ardisiacrispin B. International Journal of Molecular Sciences. PMC.
• Jansakul C, et al. (1987). Ardisiacrispin A and B, two utero-contracting saponins from Ardisia crispa. Planta Medica, 53, 405–409. PubMed.
• Podolak I, et al. (2021). Comparative Quantitative Study of Ardisiacrispin A in Extracts from Ardisia crenata Sims Varieties and Their Cytotoxic Activities. Chemistry & Biodiversity. Wiley.
• Chang X, et al. (2007). Biologically Active Triterpenoid Saponins from Ardisia japonica. Journal of Natural Products, 70(2), 179–187. ACS.
• Cytotoxic triterpenoid saponins from the roots of Ardisia crenata. PubMed.
• ShenNong Alpha — Ardisia japonica Herb (Chinese Pharmacopoeia 2020 monograph reference). Westlake University.
• Ardisia — Overview. ScienceDirect Topics (based on Journal of Ethnopharmacology, 2005).